Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.49 |
| ▸ | LPL | P06858 | 8/20 | 0.49 |
| ▸ | P4HB | P07237 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15897701 | 0.95 | LIPG (0.57) | LIPGLPLP4HBF11F2 | |
| SCHEMBL21874107 | 0.94 | AKR1C1 (0.53) | LIPGLPLP4HBF11F2 | |
| SCHEMBL9940441 | 0.91 | ALDH1A1 (0.45) | LIPGLPLP4HBF11F2 | |
| SCHEMBL14790503 | 0.87 | LIPG (0.45) | LIPGLPLP4HBF11F2 | |
| SCHEMBL3680238 | 0.87 | F11 (0.48) | LIPGLPLP4HBF11F2 | |
| SCHEMBL15912465 | 0.83 | LIPG (0.53) | LIPGLPLP4HBF11F2 | |
| SCHEMBL14709101 | 0.83 | CA1 (0.42) | LIPGLPLP4HBF11F2 | |
| SCHEMBL17215725 | 0.83 | DGAT1 (0.53) | LIPGLPL | |
| SCHEMBL22721855 | 0.82 | AKR1C1 (0.42) | LIPGLPLP4HBF11F2 | |
| SCHEMBL14790447 | 0.81 | LIPG (0.42) | LIPGLPLP4HBF11F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3679032-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20220281845-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2022-09-08 | — | — | US | disclosed |
| US-11365185-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-20200231568-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-07-23 | — | — | US | disclosed |
| EP-3679032-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2020-07-15 | — | — | EP | disclosed |
| CN-111032647-A | Lysophosphatidic acid receptor 1(LPAR1) inhibitor compounds | 伊莱利利公司 | 2020-04-17 | — | — | CN | disclosed |
| WO-2019046239-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| EP-2483251-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011041462-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | LIPG 97/4885LPL 111/4885P4HB 4753/4885 |
| US-20220281845-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LPAR1, LPAR2, LPAR5 | LIPG 231/4885LPL 221/4885P4HB 4516/4885 |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR5 | LIPG 231/4885LPL 221/4885P4HB 4516/4885 |
| US-20200231568-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LPAR1, LPAR2, LPAR3 | LIPG 224/4885LPL 210/4885P4HB 4489/4885 |
| US-11365185-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR3 | LIPG 224/4885LPL 210/4885P4HB 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.